To further assess the clinical values of NUF2, CDCA3, and KIF14 in ccRCC patients, we performed combined survival analysis and ROC analysis of METTL14 and these three m6A-modified genes, respectively. This evidence concerns the gene METTL14 and nonpapillary renal cell carcinoma.